CN106659681A - Pharmaceutical composition with improved storage stability and method for preparing the same - Google Patents

Pharmaceutical composition with improved storage stability and method for preparing the same Download PDF

Info

Publication number
CN106659681A
CN106659681A CN201680001948.6A CN201680001948A CN106659681A CN 106659681 A CN106659681 A CN 106659681A CN 201680001948 A CN201680001948 A CN 201680001948A CN 106659681 A CN106659681 A CN 106659681A
Authority
CN
China
Prior art keywords
pharmaceutical composition
medicine
soluble
formula
poorly water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680001948.6A
Other languages
Chinese (zh)
Inventor
金峰五
庆奎真
金志英
金寭林
闵范赞
尹裕晶
徐敏孝
李雄
李一雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samyang Biopharmaceuticals Corp
Original Assignee
Samyang Biopharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Biopharmaceuticals Corp filed Critical Samyang Biopharmaceuticals Corp
Publication of CN106659681A publication Critical patent/CN106659681A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A pharmaceutical composition containing a specific related compound in an amount within a specified limit and a method for preparing the same are provided.

Description

With pharmaceutical composition of storage stability for improving and preparation method thereof
Technical field
The present invention relates to have pharmaceutical composition of storage stability of improvement and preparation method thereof, relate more specifically to bag The pharmaceutical composition of the medicine of the poorly water-soluble containing amphipathic nature block polymer, wherein the content of specific related compound is maintained at Within regulation limitation；And it is related to its preparation method.
Background technology
The dissolving of the medicine of poorly water-soluble is to deliver drugs into internal key technology via oral and parenteral administration. This dissolving method includes adding in aqueous that surfactant, to form micella, then embeds (entrapping) wherein The method of the medicine of poorly water-soluble.Amphipathic nature block polymer as surfactant is comprising hydrophilic polymer blocks and dredges Waterborne polymeric block.Due to hydrophilic polymer blocks directly contact hematoglobin protein and cell membrane in vivo, therefore make With the polyethylene glycol with biocompatibility or mono methoxy polyethylene glycol etc..Hydrophobic polymer block improves and hydrophobicity medicine The compatibility of thing, therefore using with biodegradable polylactide, PGA, poly- (lactic acid-glycolide) (poly (lactic-glycolide)), polycaprolactone, polyaminoacid or poe etc..Particularly because polylactide derivative tool There is excellent biocompatibility and be hydrolyzed to harmless lactic acid in vivo, therefore they have been applied in a variety of manners medicine Carrier.Polylactide derivative has different physical propertys with its change of molecular weight, and has been developed over various forms, example Such as microballoon, nano particle, polymer gel and implant.
6th, 322, No. 805 United States Patent (USP) discloses the composition for delivering the medicine of poorly water-soluble, and it is by polymer The medicine composition of micellar drug carriers and poorly water-soluble, wherein the polymer micelle type pharmaceutical carrier is by diblock copolymer Or triblock copolymer is formed, not by cross-linking agents, it is by selected from poly- third for the diblock copolymer or triblock copolymer Lactide, PGA, poly- (lactide coglycolide), polycaprolactone and its derivative it is at least one biodegradable hydrophobic Property polymer and poly- (alkylene oxide) as hydrophilic polymer constitute, wherein the medicine of poorly water-soluble is physically embedded in into medicine In carrier and dissolve, and wherein described polymer micelle type pharmaceutical carrier forms transparent aqueous solution and by poorly water-soluble in water Medicine be effectively delivered in vivo.According to above-mentioned United States Patent (USP), PEG-PDLLA diblock copolymer be by with Lower step synthesis：Moisture is removed from mono methoxy polyethylene glycol, the stannous octoate being dissolved in toluene is added thereto to simultaneously Toluene is removed under reduced pressure, adds D, L- lactides simultaneously to carry out polymerisation in gained mixture, it is produced to dissolve to add chloroform Block copolymer, under agitation aliquot ground excessive ether is added dropwise to form precipitation, filter the precipitation of formation, and washed with ether Wash for several times.However, the method is difficult to used in large-scale production, thus it is not commercially available.Additionally, the ether for purifying may be residual In staying in final polymer micelle composition.
8th, 853, No. 351 United States Patent (USP) discloses a kind of method for preparing amphipathic nature block polymer, and it includes that (a) will Amphipathic nature block polymer is dissolved in miscible organic solvents；Add in b polymer solution that () obtains in step (a) And the aqueous solution of mixed alkali metal salt (sodium acid carbonate, sodium carbonate, saleratus, potassium carbonate or lithium carbonate)；C () is right by saltouing The solution obtained in step (b) carries out organic phase and aqueous phase separation；(d) organic phase that obtains in separating step (c) is simultaneously removed Organic solvent therein is reclaiming polymer.However, the method is related to the step of complexity, extra step is needed with except lixiviating gold Category salt and the salt (sodium chloride or potassium chloride) for saltouing, even and if being likely to that there is the metal for remaining after being removed Salt.
The impurity of medicine must be strictly controlled in all fields.Especially, active pharmaceutical ingredient (API) is come from impurity In the case of, each country sets in its drug approval guide and be derived from drug products API, known or unknown impuritie (phase Related compounds) amount the upper limit.Additionally, there is the standard that some are used in the world, ICH guide Q3A are representational one. In the guide, when medicine is examined, the amount of every kind of related compound is limited to most 0.1% or 0.2% etc. in medicine, and According to the related compound more than limitation, the information of the toxicity related data that should specify etc. is differentially suitable for.This meaning Taste the amount that related compound must be reduced during medicine is prepared, because how the related compound of medicine is made in vivo With being unknown.Therefore, for reduce related compound manufacture method and according to the characteristic of every kind of related compound (structure and Toxicity) upper limit that sets its amount is necessary factor in Control of drug quality.
The content of the invention
Technical problem
One object of the present invention is the polymer latex of the medicine for providing the poorly water-soluble containing amphipathic nature block polymer Beamforming pharmaceutical composition, it contains the specific related compound of the amount within regulation limitation.
Another object of the present invention is to provide the method for preparing described pharmaceutical composition.
Technological means
An aspect of of the present present invention provides polymeric micelle medicine composition, and it is included：Comprising hydrophilic block (A) and dredge The amphipathic nature block polymer of the purifying of aqueous block (B), and the medicine of one or more poorly water-soluble, it is selected from taxol And Docetaxel, wherein when described pharmaceutical composition is stored 6 months at 40 DEG C, it contains with the medicine of the poorly water-soluble The primary quantity of thing is the related compound represented by following formula 1 less than 0.17 weight portion of 100 weight portion meters：
[formula 1]
Wherein：
R1For H or COCH3, R2For phenyl or O (CH3)3。
The method for preparing polymeric micelle medicine composition is another aspect provides, it includes：(a) purifying bag Amphipathic nature block polymer containing hydrophilic block (A) and hydrophobic block (B)；B () will be selected from taxol and Docetaxel One or more poorly water-soluble medicine and purifying amphipathic nature block polymer dissolve in organic solvent；(c) to step Suddenly aqueous solvent is added in the solution for obtaining in (b) to form polymer micelle；When described pharmaceutical composition stores 6 at 40 DEG C When individual month, its contain by the primary quantity of the medicine of the poorly water-soluble be 100 weight portions in terms of less than 0.17 weight portion by upper The related compound that formula 1 is represented.
Beneficial effect
According to the present invention it is possible to obtain the poorly water-soluble with the related compound for reducing and the storage stability of improvement The pharmaceutical composition of medicine.
Description of the drawings
Fig. 1 be to experimental example 1 used in, through six months accelerated tests, the polymer micelle group containing taxol Compound carries out the chromatogram obtained by HPLC analyses.
(RRT 0.87 ± 0.02 (0.85～0.89), it is below for the related compound obtained in Fig. 2 display experimental examples 1 In can be with the used interchangeablies of RRT 0.87) LC/MS/MS analysis results.
The material that Fig. 3 is obtained in showing to using the mixture obtained by acid treatment taxol in experimental example 3 at RRT 0.87 Carry out the result of LC/MS/MS analyses.
The material that Fig. 4 is obtained in showing to using the mixture obtained by acid treatment taxol in experimental example 3 at RRT 0.87 The result of the Product ion scans of LC/MS/MS analyses is carried out, and through the polymerization containing taxol of six months accelerated tests The result of thing micellar pharmaceutical composition sample：
The HPLC chromatogram of (a) six months accelerated test post-consumer polymer micelle compositions；
(b) as obtained by with acid treatment taxol at the RRT 0.87 material chromatogram.
The material that Fig. 5 is obtained in showing to using the mixture obtained by acid treatment taxol in experimental example 3 at RRT 0.87 Carry out NMR analyses1H NMR analysis results.
The material that Fig. 6 is obtained in showing to using the mixture obtained by acid treatment taxol in experimental example 3 at RRT 0.87 Carry out NMR analyses13C NMR analysis results.
The material that Fig. 7 is obtained in showing to using the mixture obtained by acid treatment taxol in experimental example 3 at RRT 0.87 Carry out COSY (correlation spectrum) analysis result of NMR analyses.
The material that Fig. 8 is obtained in showing to using the mixture obtained by acid treatment taxol in experimental example 3 at RRT 0.87 Carry out HMBC (heteronuclear multiple-bond correlation spectrum) analysis result of NMR analyses.
Fig. 9 is that the chromatogram obtained by HPLC analyses is carried out in experimental example 5.
Specific embodiment
Below the present invention will be described in more detail.
The pharmaceutical composition of embodiment of the present invention includes the purifying containing hydrophilic block (A) and hydrophobic block (B) Amphipathic nature block polymer.
An embodiment of the invention, the amphipathic nature block polymer is included by hydrophilic block (A) and dredged The A-B types diblock copolymer or B-A-B type triblock copolymers of aqueous block (B) composition.
An embodiment of the invention, the amphipathic nature block polymer can be included, with the gross weight of the copolymer Gauge, the hydrophilic block of 20-95 weight %, more specifically 40-95 weight %.Additionally, the amphipathic nature block polymer can Comprising with the gross weight meter of the copolymer, the hydrophobic block of 5-80 weight %, more specifically 5-60 weight %.
An embodiment of the invention, the number-average molecular weight of the amphipathic nature block polymer can be 1,000- 50,000 dalton, more specifically 1,500-20,000 dalton.
An embodiment of the invention, the hydrophilic block is the polymer with biocompatibility and can Comprising the one kind in polyethylene glycol or derivatives thereof, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide and combinations thereof Or it is various, more specifically, it can include one or more in polyethylene glycol, mono methoxy polyethylene glycol and combinations thereof. The number-average molecular weight of hydrophilic block can be 200-20,000 dalton, more specifically 200-10,000 dalton.
An embodiment of the invention, the hydrophobic block is the polymer with biodegradability, and And can be the polymer of the monomer of derived from alpha-carboxylic acid.Specifically, it can include selected from polylactide, PGA, gather One kind of mandelic acid, polycaprolactone, Ju diox -2- ketone, polyaminoacid, poe, polyanhydride, Merlon and combinations thereof or It is various, more specifically, it can be comprising in polylactide, PGA, polycaprolactone, Ju diox -2- ketone and combinations thereof One or more.The number-average molecular weight of hydrophobic block can be 200-20,000 dalton, more specifically 200-10, 000 dalton.
An embodiment of the invention, the amphipathic block comprising poly- ('alpha '-hydroxy acids) hydrophobic polymer block Copolymer can be synthesized by known ring-opening polymerization method, and methods described uses the hydrophilic polymer with hydroxyl as drawing Send out agent and 'alpha '-hydroxy acids internal ester monomer.For example, with the hydrophilic polyglycol with hydroxyl or mono methoxy polyethylene glycol to draw Agent is sent out, L- lactides or D, L- lactide can pass through ring-opening polymerisation.According to present in the hydrophilic block as initiator The number of hydroxyl, can synthesize diblock copolymer or triblock copolymer.In ring-opening polymerisation, it is possible to use organic metal is urged Agent, such as tin oxide, lead oxide, tin octoate, sad antimony etc., preferably use with biofacies when medical polymer is prepared The tin octoate of capacitive.
In embodiments of the invention, using the copolymer of purifying as amphipathic nature block polymer.According to the present invention Preferred embodiment, amphipathic nature block polymer is by the copolymer of sublimation purification.
Sublimation purification can preferably 80 DEG C less than 120 DEG C, more preferably 80-100 DEG C at a temperature of, and excellent Preferred 10-74 hours, more are carried out under the pressure for selecting the vacuum below 10 supports, below more preferably 5 supports, below more preferred 1 support It is preferred that 10-48 hours, more preferred 24-48 hours.Carry out purifying by distillation under these conditions and can make dividing for copolymer Son amount change minimizes and removes from copolymer impurity.
The pharmaceutical composition of the present invention includes the medicine selected from taxol and one or more poorly water-soluble of Docetaxel Thing is used as active component.
An embodiment of the invention, pharmaceutical composition can be also included as other active component except Japanese yew The medicine of one or more poorly water-soluble outside alcohol and Docetaxel.As such other active component, can make 7- Epitaxols, t- acetyl paclitaxels, 10- deacetylate taxols, 10- deacetylate -7- tables are selected from one or more Taxol, 7- xylosyl taxols, 10- deacetylate -7- glutaryl taxols, 7-N, N- dimethylglycinamidyl taxols, 7- The taxane anticancer agents of L- alanyls taxol and Cabazitaxel (cabazitaxel).
The pharmaceutical composition of embodiment of the present invention can be included, based on the amphipathic nature block polymer of 100 weight portions, The medicine of 0.1-50 weight portions, the more specifically poorly water-soluble of 0.5-30 weight portions.Compared with the amount of amphipathic nature block polymer, If the amount of the medicine of poorly water-soluble is very little, the weight of the amphipathic copolymer that every kind of medicine is used is higher, therefore reconstructs Time can increase.On the other hand, if the amount of the medicine of poorly water-soluble is too many, the medicine that there may be poorly water-soluble quickly sinks The problem in shallow lake.
As used herein " initial " amount of the medicine of poorly water-soluble refers to the water solubility mixed when preparing pharmaceutical composition The weight of poor medicine.
In embodiments of the invention, when described pharmaceutical composition under acceleration conditions (40 DEG C) storage 6 months when, its Contain, count by 100 weight portions of the primary quantity of the medicine of the poorly water-soluble, less than being represented by following formula 1 for 0.17 weight portion Related compound：
[formula 1]
Wherein：
R1For H or COCH3, R2For phenyl or O (CH3)3。
An embodiment of the invention, the medicine of poorly water-soluble is taxol, and related compound may include following formula The compound that 1a is represented：
[formula 1a]
When under acceleration conditions (40 DEG C) storage 6 months when, the pharmaceutical composition of embodiment of the present invention can contain, with institute The primary quantity for stating the medicine of poorly water-soluble is 100 weight portion meters, less than 0.17 weight portion, below preferably 0.15 weight portion, more excellent Select below 0.1 weight portion, below more preferred 0.08 weight portion, most preferably 0.04 weight portion Formula 1 below (particularly formula 1a) Related compound.
When under strict conditions (80 DEG C) storage 3 weeks when, the pharmaceutical composition of embodiment of the present invention can contain, with described The primary quantity of the medicine of poorly water-soluble be 100 weight portion meters, less than below 0.76 weight portion, preferably 0.5 weight portion, more preferably Below 0.4 weight portion, below more preferred 0.2 weight portion, the phase of most preferably 0.15 weight portion Formula 1 below (particularly formula 1a) Related compounds.
In embodiments of the invention, the pharmaceutical composition of the specific related compound containing the amount within regulation limitation It is commercially available composition, because it can be mass produced.
In one embodiment, pharmaceutical composition of the invention is entirely free of ether, such as ether.
In one embodiment, pharmaceutical composition of the invention does not have completely a slaine, for example alkali metal salt and/or For the salt saltoutd, such as NaCl or KCl.
It is prepared by the method that the pharmaceutical composition of embodiment of the present invention can pass through to comprise the following steps：A () purifying is included The amphipathic nature block polymer of hydrophilic block (A) and hydrophobic block (B)；B () is by selected from taxol and Docetaxel The medicine of one or more poorly water-soluble and the amphipathic nature block polymer of purifying dissolve in organic solvent；(c) to step Suddenly aqueous solvent is added in the solution for obtaining in (b) to form polymer micelle.
The purifying of amphipathic nature block polymer is as described above, polymer micelle can be formed with conventional method.
In the method for preparing pharmaceutical composition of embodiment of the present invention, it is possible to use be selected from alcohol (such as second Alcohol), acetone, tetrahydrofuran, acetic acid, the miscible organic solvents of acetonitrile and dioxane and combinations thereof as organic solvent, But it is not limited to this.Further, it is possible to use selected from conventional water, distilled water, distilled water for injection, physiological saline, 5% glucose, One kind in buffer solution and combinations thereof is used as aqueous solvent, but not limited to this.
The method for preparing pharmaceutical composition of embodiment of the present invention may additionally include remove after the step (a) it is organic Solvent.
In embodiments, methods described may also include addition lyophilization aid to freeze micelle composition.Can be lyophilized Composition adds lyophilization aid to maintain pie.In another embodiment, lyophilization aid can be in sugar and sugar alcohol One or more.Sugar can be one or more in lactose, maltose, sucrose or trehalose.Sugar alcohol can be choosing One or more from mannitol, sorbierite, maltitol, xylitol and lactitol.Lyophilization aid can also be used to promote to freeze Uniform dissolution of the dry polymer micelle composition in reconstruct.Based on the gross weight of freeze-dried composition, the content of lyophilization aid Can be 1-90 weight %, particularly 1-60 weight %, more particularly 10-60 weight %.
By following examples, the present invention will be described in more detail.However, these embodiments are intended merely to illustrate this It is bright, and embodiment limited the scope of the present invention never in any form.
Embodiment
Preparation example 1：The diblock copolymer (mPEG-PDLLA) being made up of mono methoxy polyethylene glycol and D, L- lactide Synthesis and by sublimation method purify
By 150g mono methoxy polyethylene glycols, (000) mPEG, number-average molecular weight=2 are added to equipped with agitator In 500ml round-bottomed flasks, and 2 hours are stirred under 120 DEG C of vacuum conditions to remove moisture.In being dissolved in 200 μ l toluene 0.15g tin octoates (Sn (Oct)2) reaction flask is added to, and be stirred for 1 hour under vacuum to distill and remove first Benzene.150g D are subsequently adding, L- lactides simultaneously stir under nitrogen atmosphere to dissolve.In D, after L- lactides are completely dissolved, will Reactor tight seal, and polymerisation is carried out at 120 DEG C 10 hours.After reaction terminating, under bar magnet stirring, by reactor Vavuum pump is connected to, product is purified 7 hours under the pressure of 1 support or lower by sublimation method, obtains 262g molten conditions mPEG-PDLLA.By with1H-NMR analyses obtain the end group-OCH with regard to mono methoxy polyethylene glycol3Appropriate peak phase To intensity, so as to calculate molecular weight (Mn：～3740).
Preparation example 2：Diblock copolymer (mPEG-PDLLA) is purified by sublimation method
The 30g mPEG-PDLLA carried out before purge process obtained in the polymerization process of preparation example 1 are added Dissolve in single neck flask and at 80 DEG C.Under bar magnet stirring, reactor is connected into vavuum pump, and in 1 support or lower Pass through sublimation method purified product 24 hours and 48 hours under pressure.
Preparation example 3：Diblock copolymer (mPEG-PDLLA) is purified by sublimation method
In addition to cleansing temp is 100 DEG C, by being purified with the identical method of preparation example 2.
Preparation example 4：Diblock copolymer (mPEG-PDLLA) is purified by sublimation method
In addition to cleansing temp is 120 DEG C, by being purified with the identical method of preparation example 2.
Preparation example 5：Using aluminum oxide (Al2O3) pass through purification via adsorption-based process diblock copolymer (mPEG-PDLLA)
The 30g mPEG-PDLLA carried out before purge process obtained in the polymerization process of preparation example 1 are added In single neck flask and add acetone (60ml) dissolve.It is added thereto to aluminum oxide (15g) and is thoroughly mixed.By single neck flask and rotation Turn evaporimeter connection, content mixes 2 hours under 50 DEG C, 60rpm.Then solution used at room temperature PTFE filter paper (1 μm) Filter to remove aluminum oxide.Filtered acetone soln is distilled under 60 DEG C of vacuum using rotary evaporator and removes acetone, by This obtains the mPEG-PDLLA of purifying.By with1H-NMR analyses obtain the end group-OCH with regard to mono methoxy polyethylene glycol3 Appropriate peak relative intensity, so as to calculate molecular weight (Mn：～3690).
The change of molecular weight of the mPEG-PDLLA of the purification condition in above-mentioned preparation example 2-5 is shown in table 1 below.
Table 1
From the results shown in Table 1, as cleansing temp is uprised, the decrement of the molecular weight of mPEG-PDLLA increases. 80-100 DEG C and 24-48 hours, particularly 100 DEG C and the purification condition of 24 hours can be considered as effective.
Comparative example 1：The preparation of the polymer micelle composition containing taxol
The mPEG-PDLLA obtained in 1g taxols and 5g preparation examples 1 is weighed, 4ml ethanol is added, stirs straight at 60 DEG C It is completely dissolved to form settled solution to mixture.Then the rotary evaporator equipped with round-bottomed flask is used to reduce pressure at 60 DEG C steaming Evaporate 3 hours to remove ethanol.Then temperature is reduced into 50 DEG C, adds the distilled water under 140ml room temperatures, and carry out reaction until Solution becomes the blueness clarified to form polymer micelle.2.5g Lactis Anhydrouses are added thereto to as lyophilization aid and make its complete CL, is filtered using filter of the aperture for 200nm, and freeze-drying, obtains the polymer powder glue containing taxol Beam composition.
Embodiment 1：The preparation of the polymer micelle composition containing taxol
In addition to using and purifying the mPEG-PDLLA of 24 hours in preparation example 3, by with the identical method of comparative example 1 Prepare the polymer micelle composition containing taxol.
Embodiment 2：The preparation of the polymer micelle composition containing taxol
In addition to using the mPEG-PDLLA purified in preparation example 5, contained by preparing with the identical method of comparative example 1 There is the polymer micelle composition of taxol.
Experimental example 1：Related compound is separated by liquid chromatogram
To accommodating through 6 months accelerated test (temperature：40 DEG C) 100mg contain the polymer micelle group of taxol 16.7ml deionized waters (DW) are added in the bottle of compound, content is completely dissolved, the liquid of total amount is taken and is transferred to 20ml In volumetric flask, it is 20ml (5.0mg/ml) to be diluted to graticule and make cumulative volume.Take the 2ml liquid and be transferred in 10ml volumetric flasks, It is 10ml (1mg/ml) to add acetonitrile to graticule to make cumulative volume.For above-mentioned composition, using following liquid chromatography phase is separated Related compounds and Fractional Collections.
Liquid phase chromatogram condition
1) post：Poroshell 120PFP (4.6 × 150mm, 2.7 μm, Agilent)
2) mobile phase：A：DW/B：Acetonitrile
Time (min) A% B%
0.00 65 35
25.00 45 55
28.00 45 55
30.00 65 35
35.00 65 35
3) flow velocity：0.6ml/min (minute)
4) injection volume：10μl
5) detector：Ultravioblet spectrophotometer (measurement wavelength：227nm)
The chromatogram of the HPLC analyses for obtaining shows in FIG.
Experimental example 2：Qualitative analysis is carried out to related compound using LC/MS/MS
By the MS scannings and Product ion scans of liquid chromatograph-mass spectrometer (LC/MS/MS) to detached in experimental example 1 Related compound (RRT：0.87 ± 0.02 (0.85～0.89)) carry out qualitative analysis.In following measurement, using liquid phase color The series of spectrum 1200 and electrospray ionization mass spectrometry instrument 6400 serial (Agilent, the U.S.) are used as LC/MS/MS.Analysis condition is as follows.
Liquid phase chromatogram condition
1) post：Poroshell 120PFP (4.6 × 150mm, 2.7 μm, Agilent)
2) mobile phase：A：DW/B：Acetonitrile
Time (min) A% B%
0.00 65 35
25.00 45 55
28.00 45 55
30.00 65 35
35.00 65 35
3) flow velocity：0.6ml/min
4) injection volume：10μl
5) detector：Ultravioblet spectrophotometer (measurement wavelength：227nm)
The condition of electrospray ionization mass spectrometry instrument
1) ionize：Electron spray ionisation, just (ESI+)
2) MS methods：MS2 scannings/Product ion scans
3) ion gun：Agilent Jet Stream ESI
4) nebulizer gas (pressure)：Nitrogen (35psi)
5) ion spray voltage：3500V
6) dry gas temperature (flow velocity)：350℃℃(7L/min)
7) sheath temperature degree (flow velocity)：400℃(10L/min)
8) fragmentation voltage：135V
9) spray nozzle voltage：500V
10) pond accelerating potential：7V
11)EMV：0V
12) collision energy：22V
13) precursor ion：m/z 894.2
14) mass scan range：M/z 100～1500
The material for analysis for separating from detection-phase and produce is set to flow in a mass spectrometer, while qualitative point The detection ion of phase separation related compounds, and select mass spectrographic characteristic ion [M+Na].
Experimental example 3：LC/MS/MS analyses are carried out in the material of 0.87 time acquisition of RRT to the taxol of acid treatment
As the result of the qualitative analysis in experimental example 2, at HPLC point of the polymer micelle composition containing taxol Material in analysis at RRT 0.87 is considered as the material produced when taxol is present under acid condition.In order to demonstrate,prove Real this point, by adding 1N HCl prepare compounds in taxol, by using preparative LC, separates and Fractional Collections Material at RRT 0.87, and it is analyzed by LC/MS/MS.LC/MS/MS analysis result show in figure 3, LC/ The result one of the polymer micelle composition sample of Product ion scans result and six months accelerated tests of Jing in MS/MS analyses Rise and show in the diagram.
According to analysis result, shown and related compound by the material obtained at RRT 0.87 with acid treatment taxol (RRT:0.87 ± 0.02 (0.85～0.89)) HPLC peaks at the HPLC peaks of identical position, the related compound is Jing The related compound crossed in the polymer micelle composition containing taxol of the invention of six months accelerated tests.Additionally, by MS Product ion scans in these peaks show identical pattern, thus it is confirmed that two kinds of materials have identical structure.
Experimental example 4：The NMR analyses of the material that the taxol of acid treatment is obtained at RRT 0.87
To be separated by the compound for adding 1N HCl to prepare in taxol and the Fractional Collections at RRT 0.87, passed through NMR analyzes its structure.In NMR analyses,1H NMR analysis result show in Figure 5,13The result of C NMR analyses is displayed in In Fig. 6, the result of COSY (correlation spectrum) analyses shows in the figure 7, and HMBC (heteronuclear multiple-bond correlation spectrum) analyses are shown in Fig. 8 In.
According to analysis result, can confirm that the material by being obtained at RRT 0.87 with acid treatment taxol (is passed through Related compound in the polymer micelle composition containing taxol of the embodiment of the present invention of six months accelerated tests (RRT：0.87 ± 0.02 (0.85～0.89)) be Japanese yew alcohol and water following combining form compound.
The combining form of taxol and a molecular water：C47H53NO15(871.94g/mol)。
The condition of NMR spectrum
1. 1H NMR
1) NMR equipment：It is equipped with the Brucker DRX-300 of temperature controller, AVANCE-400
2) sample/solvent：1-10mg samples/0.6mL chloroform-d in the NMR pipes that external diameter is 5mm are (in all NMR realities In testing, using identical sample)
3) pop one's head in：Brucker 5mm QNP or C-H dual probes
4) 90 ° of pulse widths of proton/excite angle/capture time：10.0-11.0 microsecond/30 °/～5.0 seconds
5) relaxation delay/scanning times：1.0～5.0 seconds/4～64
2. 13C NMR
1) pop one's head in：Brucker 5mm QNP or C-H dual probes
2) 90 ° of pulse widths of carbon/excite angle/capture time：10.0 microsecond/30 °/2.0～3.0 second
3) relaxation delay/scanning times：2.0～5.0 seconds/be more than 5,000
3.COSY
1) NMR equipment：Brucker AVANCE-400
2) pop one's head in：Brucker 5mm QNP
3) pulse train：Cosygp pulse trains
4) 90 ° of pulse width/capture times of proton：11.0 microsecond/0.4～1.6 second
5) experiment number of relaxation delay/scanning times/ω 1：0.5～2.0 second/32～48/400～500
4.HMBC
1) NMR equipment：Brucker AVANCE-400
2) pop one's head in：Brucker 5mm reversely pop one's head in
3) pulse train：Inv4gptp pulse trains (for HMQC)/inv4gplprnd pulse trains (for HMBC)
4) 90 ° of proton, 90 ° of pulse width/carbon pulse width/acquisition time：7.5 microsecond/17～18 microsecond/0.15～0.2 Second
5) experiment number of the scanning times/ω 1 of the scanning times/HMBC of relaxation delay/HMQC：1.0～2.0 seconds/32 ～96/224/128～256
6) temperature/1/2 (JCH)：300K/3.5 milliseconds
Experimental example 5：The contrast test of the storage stability of the polymer micelle of (80 DEG C) containing medicine under strict conditions
By the polymer micelle composition of the taxol prepared in comparative example 1 and embodiment 1-2 in 80 DEG C of baking oven Kept for 3 weeks, then with HPLC analysed compositions comparing the amount of related compound.By the way that micelle composition is dissolved in into 80% second In the nitrile aqueous solution and it is diluted to paclitaxel concentration for 600ppm to prepare test solution.Chromatogram obtained by HPLC analyses is displayed in In Fig. 9, and during the changes of contents (%) of the related compound according to the severe test time is shown in table 2 below.
HPLC conditions
Post：2.7 μm of diameter, Poroshell 120PFP (4.6 × 150mm, 2.7 μm) (Agilent posts)
Mobile phase
Time (min) Water:Acetonitrile
0～25 65:35→45:55
25～28 45:55
28～30 45:55→65:35
30～35 65:35
Detector：Ultravioblet spectrophotometer (227nm)
Flow velocity：0.6ml/min
The amount (%)=100 (Ri/Ru) of each related compound
Ri：The area of the every kind of related compound detected in test solution analysis
Ru：The summation of all peak areas detected in test solution analysis
[table 2]
*RRT 0.87±0.02：Taxol, oxetanes opened loop compound
RRT 0.96±0.02：Taxol, oxetanes opened loop compound
RRT 1.00:Taxol
RRT 1.10±0.02：Taxol, L- lactide compound of reactions
RRT 1.12±0.02：Taxol, D- lactide compound of reactions
RRT 1.44±0.05：Taxol, removes hydrate
Knowable to table 2 and Fig. 9, compared with the composition of comparative example 1, the polymeric micelle medicine composition of embodiment 1 or 2 Stability be improved, the reduction of taxol amount is relatively small, therefore can more stably maintain contained drug in composition Effect.
Experimental example 6：The contrast test of the storage stability of the polymer micelle of (40 DEG C) containing medicine under acceleration conditions
Except will respectively in comparative example 1 and embodiment 1 prepare taxol polymer micelle composition in stability Outside being kept for 6 months at 40 DEG C in test instrument, by being tested with the identical method of experimental example 5.Will be according to accelerated test The changes of contents of the related compound of time is shown in table 3 below.
[table 3]
Above-mentioned result of the test is shown in the test that to different batches 3 kinds or more kinds of polymer micelle compositions are carried out The mean value of the amount of every kind of related compound and taxol.
By experimental example 6, it has proved that when at a temperature of accelerating storage (40 DEG C) storage 6 months when, the polymerization of embodiment 1 Thing micellar pharmaceutical composition has related compound more lower amount of than the composition of comparative example 1.

Claims (12)

1. polymeric micelle medicine composition, it is included：
Amphipathic nature block polymer comprising hydrophilic block (A) and the purifying of hydrophobic block (B), and
The medicine of one or more poorly water-soluble, it is selected from taxol and Docetaxel,
Wherein when described pharmaceutical composition is stored 6 months at 40 DEG C, it contains with the initial of the medicine of the poorly water-soluble Measure the related compound represented by following formula 1 less than 0.17 weight portion for 100 weight portion meters：
[formula 1]
Wherein：
R1For H or COCH3, R2For phenyl or O (CH3)3。
2. pharmaceutical composition according to claim 1, the compound of wherein formula 1 is the compound with following formula 1a：
[formula 1a]
3. pharmaceutical composition according to claim 1, it contains with the primary quantity of the medicine of the poorly water-soluble as 100 weights 0.15 weight portion of amount part meter or the related compound of less formula 1.
4. pharmaceutical composition according to claim 3, it contains with the primary quantity of the medicine of the poorly water-soluble as 100 weights 0.1 weight portion of amount part meter or the related compound of less formula 1.
5. pharmaceutical composition according to claim 4, it contains with the primary quantity of the medicine of the poorly water-soluble as 100 weights 0.08 weight portion of amount part meter or the related compound of less formula 1.
6. pharmaceutical composition according to claim 5, it contains with the primary quantity of the medicine of the poorly water-soluble as 100 weights 0.04 weight portion of amount part meter or the related compound of less formula 1.
7. pharmaceutical composition according to claim 1, when described pharmaceutical composition is stored 3 weeks at 80 DEG C, it contains Count by 100 weight portions of the primary quantity of the medicine of the poorly water-soluble, less than the related compound of the formula 1 of 0.76 weight portion.
8. pharmaceutical composition according to claim 1, wherein the hydrophilic block (A) comprising selected from polyethylene glycol or its One or more in derivative, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylamide and combinations thereof.
9. pharmaceutical composition according to claim 1, wherein the hydrophobic block (B) is comprising selected from polylactide, poly- Glycolide, poly- mandelic acid, polycaprolactone, Ju diox -2- ketone, polyaminoacid, poe, polyanhydride, Merlon and its group One or more for closing.
10. pharmaceutical composition according to claim 1, wherein the hydrophilic block (A) is polyethylene glycol or single methoxy Base polyethylene glycol, the hydrophobic block (B) is polylactide.
11. pharmaceutical compositions according to claim 1, wherein the number-average molecular weight of the hydrophilic block (A) is 200- 20,000 dalton, the number-average molecular weight of the hydrophobic block (B) is 200-20,000 dalton.
12. pharmaceutical compositions according to claim 1, wherein the amphipathic nature block polymer is by more than 80 DEG C And less than 120 DEG C at a temperature of and 10 supports below vacuum pressure under the 10-74 hours purifying that distils obtain.
CN201680001948.6A 2015-07-28 2016-07-28 Pharmaceutical composition with improved storage stability and method for preparing the same Pending CN106659681A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0106627 2015-07-28
KR20150106627 2015-07-28
PCT/KR2016/008267 WO2017018818A1 (en) 2015-07-28 2016-07-28 Pharmaceutical composition with improved storage stability and method for preparing the same

Publications (1)

Publication Number Publication Date
CN106659681A true CN106659681A (en) 2017-05-10

Family

ID=57885186

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680001948.6A Pending CN106659681A (en) 2015-07-28 2016-07-28 Pharmaceutical composition with improved storage stability and method for preparing the same

Country Status (13)

Country Link
EP (1) EP3328435A4 (en)
JP (1) JP2018521103A (en)
KR (1) KR101787451B1 (en)
CN (1) CN106659681A (en)
AU (1) AU2016299546B2 (en)
BR (1) BR112018001725A2 (en)
CA (1) CA2993925A1 (en)
HK (1) HK1249442A1 (en)
IL (1) IL257188A (en)
MX (1) MX2018001221A (en)
RU (1) RU2018107057A (en)
WO (1) WO2017018818A1 (en)
ZA (1) ZA201801188B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102144479B1 (en) * 2018-05-24 2020-08-13 주식회사 덱스레보 Composition for tissue repair treatment and methods of manufacturing the same
KR102251192B1 (en) * 2020-08-07 2021-05-13 주식회사 덱스레보 Composition for tissue repair treatment and methods of manufacturing the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1571816A (en) * 2001-10-18 2005-01-26 株式会社三养社 Polymeric michelle composition with improved stability
CN101910274A (en) * 2007-12-31 2010-12-08 株式会社三养社 Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
CN101910246A (en) * 2007-12-31 2010-12-08 株式会社三养社 Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof
CN102218027A (en) * 2011-04-22 2011-10-19 上海谊众生物技术有限公司 Polymer micelle lyophilized agent encapsulating insoluble antitumor drug
CN102264351A (en) * 2008-12-26 2011-11-30 株式会社三养社 Preparation method of polymeric micelles composition containing poorly water-soluble drug
CN103768013A (en) * 2014-01-17 2014-05-07 丽珠医药集团股份有限公司 Paclitaxel polymer micelle by using refined amphiphilic block copolymer as carrier

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550157B2 (en) * 2000-05-12 2009-06-23 Samyang Corporation Method for the preparation of polymeric micelle via phase separation of block copolymer
US7217770B2 (en) * 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
ES2353653T3 (en) 2007-03-06 2011-03-03 Cell Therapeutics Europe S.R.L. METHOD FOR DETERMINING THE AMOUNT OF CONJUGATED TAXAN IN POLYGLUTAMIC ACID-TAXAN CONJUGATES.
US9801818B2 (en) * 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1571816A (en) * 2001-10-18 2005-01-26 株式会社三养社 Polymeric michelle composition with improved stability
CN101910274A (en) * 2007-12-31 2010-12-08 株式会社三养社 Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
CN101910246A (en) * 2007-12-31 2010-12-08 株式会社三养社 Highly pure amphiphilic copolymer comprising hydrophobic block from alpha-hydroxy acid and process for the preparation thereof
CN102264351A (en) * 2008-12-26 2011-11-30 株式会社三养社 Preparation method of polymeric micelles composition containing poorly water-soluble drug
CN102218027A (en) * 2011-04-22 2011-10-19 上海谊众生物技术有限公司 Polymer micelle lyophilized agent encapsulating insoluble antitumor drug
CN103768013A (en) * 2014-01-17 2014-05-07 丽珠医药集团股份有限公司 Paclitaxel polymer micelle by using refined amphiphilic block copolymer as carrier

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIUTARU ET AL: ""A HPLC validated assay of paclitaxel"s related impurities in pharmaceutical forms containing Cremophor® EL"", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 *
KUMAR ET AL: ""Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation"", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 *
潘帅奇: ""紫杉醇mPEG-PLA共聚物胶束治疗脑胶质瘤的研究"", 《中国优秀硕士论文全文数据库 医药卫生科技辑》 *

Also Published As

Publication number Publication date
KR101787451B1 (en) 2017-10-19
HK1249442A1 (en) 2018-11-02
BR112018001725A2 (en) 2018-09-18
CA2993925A1 (en) 2017-02-02
EP3328435A4 (en) 2019-03-13
AU2016299546B2 (en) 2019-05-02
WO2017018818A1 (en) 2017-02-02
EP3328435A1 (en) 2018-06-06
RU2018107057A3 (en) 2019-08-28
ZA201801188B (en) 2018-12-19
JP2018521103A (en) 2018-08-02
IL257188A (en) 2018-03-29
MX2018001221A (en) 2018-04-24
RU2018107057A (en) 2019-08-28
AU2016299546A1 (en) 2018-03-08
KR20170015199A (en) 2017-02-08

Similar Documents

Publication Publication Date Title
JP6147427B2 (en) Preparation method of lyophilized formulation of nanopolymer micelle of docetaxel
Jelonek et al. Self-assembled filomicelles prepared from polylactide/poly (ethylene glycol) block copolymers for anticancer drug delivery
KR100502840B1 (en) A block copolymer micelle composition having an improved drug loading capacity
JP6165920B2 (en) Polymer conjugate of active ingredient, production method thereof and polymer intermediate thereof
CN107850584B (en) Method for analyzing related substances of pharmaceutical composition containing polymer carrier
CN106659681A (en) Pharmaceutical composition with improved storage stability and method for preparing the same
US11464861B2 (en) Pharmaceutical composition with improved storage stability and method for preparing the same
CN106559983A (en) With pharmaceutical composition of storage stability for improving and preparation method thereof
CN106659680A (en) Pharmaceutical composition with improved storage stability and method for preparing the same
CN107998405A (en) The preparation method and application of the new NO donator type polymeric micelle compositions comprising insoluble drug
US20170028066A1 (en) Pharmaceutical composition with improved storage stability and method for preparing the same
CN107466231A (en) With improved pharmaceutical composition of storage stability and preparation method thereof
US20170027866A1 (en) Pharmaceutical composition with improved storage stability and method for preparing the same
US20170028067A1 (en) Pharmaceutical composition with improved storage stability and method for preparing the same
Stafast et al. End-functionalized diblock copolymers by mix and match of poly (2-oxazoline) and polyester building blocks
Göppert et al. How introduction of hydrolyzable moieties in POx influences particle formation–a library approach based on block copolymers comprising polyesters
KR101902906B1 (en) Related substance as a standard for evaluation of a pharmaceutical composition containing a polymeric carrier

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170510

WD01 Invention patent application deemed withdrawn after publication